{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:11:18Z","timestamp":1787008278206,"version":"build-2736575974"},"reference-count":32,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this study was to evaluate atomoxetine treatment effects in attention-deficit\/hyperactivity disorder (ADHD-only), attention-deficit\/hyperactivity disorder with comorbid dyslexia (ADHD+D), or dyslexia only on ADHD core symptoms and on sluggish cognitive tempo (SCT), working memory, life performance, and self-concept.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Children and adolescents (10\u201316 years of age) with ADHD+D (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =124), dyslexia-only (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =58), or ADHD-only (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =27) received atomoxetine (1.0\u20131.4\u2009mg\/kg\/day) or placebo (ADHD-only subjects received atomoxetine) in a 16 week, acute, randomized, double-blind trial with a 16 week, open-label extension phase (atomoxetine treatment only). Changes from baseline were assessed to weeks 16 and 32 in ADHD Rating Scale-IV-Parent-Version:Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv); ADHD Rating Scale-IV-Teacher-Version (ADHDRS-IV-Teacher-Version); Life Participation Scale\u2014Child- or Parent-Rated Version (LPS); Kiddie-Sluggish Cognitive Tempo (K-SCT) Interview; Multidimensional Self Concept Scale (MSCS); and Working Memory Test Battery for Children (WMTB-C).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At week 16, atomoxetine treatment resulted in significant (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;0.05) improvement from baseline in subjects with ADHD+D versus placebo on ADHDRS-IV-Parent:Inv Total (primary outcome) and subscales, ADHDRS-IV-Teacher-Version Inattentive subscale, K-SCT Interview Parent and Teacher subscales, and WMTB-C Central Executive component scores; in subjects with Dyslexia-only, atomoxetine versus placebo significantly improved K-SCT Youth subscale scores from baseline. At Week 32, atomoxetine-treated ADHD+D subjects significantly improved from baseline on all measures except MSCS Family subscale and WMTB-C Central Executive and Visuo-spatial Sketchpad component scores. The atomoxetine-treated dyslexia-only subjects significantly improved from baseline to week 32 on ADHDRS-IV-Parent:Inv Inattentive subscale, K-SCT Parent and Teacher subscales, and WMTB-C Phonological Loop and Central Executive component scores. The atomoxetine-treated ADHD-only subjects significantly improved from baseline to Week 32 on ADHDRS-Parent:Inv Total and subscales, ADHDRS-IV-Teacher-Version Hyperactive\/Impulsive subscale, LPS Self-Control and Total, all K-SCT subscales, and MSCS Academic and Competence subscale scores.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Atomoxetine treatment improved ADHD symptoms in subjects with ADHD+D and ADHD-only, but not in subjects with dyslexia-only without ADHD. This is the first study to report significant effects of any medication on SCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration:<\/jats:title>\n                    <jats:p>\n                      This study was registered at:\n                      <jats:uri xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/ct2\/home\">http:\/\/clinicaltrials.gov\/ct2\/home<\/jats:uri>\n                      , NCT00607919.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2013.0054","type":"journal-article","created":{"date-parts":[[2013,11,9]],"date-time":"2013-11-09T09:16:40Z","timestamp":1383988600000},"page":"605-613","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":45,"title":["Atomoxetine Improved Attention in Children and Adolescents with Attention-Deficit\/Hyperactivity Disorder and Dyslexia in a 16 Week, Acute, Randomized, Double-Blind Trial"],"prefix":"10.1177","volume":"23","author":[{"given":"Linda","family":"Wietecha","sequence":"first","affiliation":[{"name":"Lilly USA, LLC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Williams","sequence":"additional","affiliation":[{"name":"inVentiv Health Clinical, LLC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Shaywitz","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennett","family":"Shaywitz","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Hooper","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon B.","family":"Wigal","sequence":"additional","affiliation":[{"name":"University of California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dunn","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"McBurnett","sequence":"additional","affiliation":[{"name":"University of California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,11,1]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4thText RevisionWashington DC: American Psychiatric Association 2000."},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0023961"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/87565641.2010.549877"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Bracken BA. Multidimensional Self Concept Scale (MSCS) Examiner's Manual. Austin TX: PRO-ED 1992.","DOI":"10.1037\/t01247-000"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9981-9"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1207\/S15374424JCCP3101_14"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2009.0029"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"DuPaul G Power T Anastopolous A Reid R. ADHD Rating Scale-IV: Checklists Norms Clinical Interpretation. New York: Guilford Publications 1998.","DOI":"10.1037\/t00680-000"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10802-010-9436-8"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/87565641.2010.494748"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:JACP.0000037779.85211.29"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.70.5.1099"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedn.2010.02.004"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7610.2005.00410.x"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199707000-00021"},{"key":"e_1_3_3_17_1","article-title":"Validity of the sluggish cognitive tempo symptom dimension in children: Sluggish cognitive tempo, ADHD-inattention as distinct symptom dimensions","author":"Lee S","year":"2013","unstructured":"Lee S, , Burns GL, , Snell J, , McBurnett K. Validity of the sluggish cognitive tempo symptom dimension in children: Sluggish cognitive tempo, ADHD-inattention as distinct symptom dimensions. J Abnorm Child Psychol, 2013[Epub ahead of print].","journal-title":"J Abnorm Child Psychol"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010377530749"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10802-010-9429-7"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0016600"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e318064675f"},{"key":"e_1_3_3_22_1","volume-title":"Working Memory Test Battery for Children (WMTB-C) Manual","author":"Pickering S","year":"2001","unstructured":"Pickering S, , Gathercole S. Working Memory Test Battery for Children (WMTB-C) Manual. London: Pearson Assessment, 2001."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsm063"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.7748\/ns.25.24.35.s50"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0022219411407772"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0954579408000631"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10802-011-9488-4"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/09658210244000450"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-3-40"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/09297041003671176"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cortex.2010.06.009"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.30310"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10802-007-9108-5"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2013.0054","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2013.0054","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2013.0054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:55:46Z","timestamp":1777388146000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2013.0054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1089\/cap.2013.0054"],"URL":"https:\/\/doi.org\/10.1089\/cap.2013.0054","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}